

◀ September							October 2019							November ▶						
Sun	Mon	Tue	Wed	Thu	Fri	Sat	Sun	Mon	Tue	Wed	Thu	Fri	Sat	Sun	Mon	Tue	Wed	Thu	Fri	Sat
6	7 Day 1 Labs Clinic Visit Obinutuzumab IV	8 Labs Obinutuzumab IV	9	10	11	12	13	14 Day 8	15 Labs Obinutuzumab IV	16	17	18	19	20	21 Day 15	22 Labs Obinutuzumab IV	23	24	25	26
27	28 Day 22	29 Labs Clinic Venetoclax 20mg (infusion for 6-8hr lab monitoring)	30 Labs Infusion (lab follow-up) Venetoclax 20mg	31 Venetoclax 20mg																

◀ October							November 2019							December ▶						
Sun	Mon	Tue	Wed	Thu	Fri	Sat	Sun	Mon	Tue	Wed	Thu	Fri	Sat	Sun	Mon	Tue	Wed	Thu	Fri	Sat
					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16

					Venetoclax 20 mg	Venetoclax 20 mg
3	4 Day 1	5 Labs Clinic Venetoclax 50 mg Infusion – Obinutuzuma b IV PLUS infusion for 6-8hr lab monitoring	6 Labs Infusion (lab follow-up) Venetoclax 50 mg	7	8 Venetoclax 50 mg	9 Venetoclax 50 mg
10	11 Day 8	12 Labs Clinic Venetoclax 100 mg	13 Venetoclax 100 mg	14 Venetoclax 100 mg	15 Venetoclax 100 mg	16 Venetoclax 100 mg
17	18 Day 15	19 Labs Clinic Venetoclax 200 mg	20 Venetoclax 200 mg	21 Venetoclax 200 mg	22 Venetoclax 200 mg	23 Venetoclax 200 mg
24	25 Day 22	26 Labs Clinic Venetoclax 400 mg	27 Venetoclax 400 mg	28 Venetoclax 400 mg	29 Venetoclax 400 mg	30 Venetoclax 400 mg

◀ November						
December 2019						
January ▶						
Sun	Mon	Tue	Wed	Thu	Fri	Sat

1	2	3 Day 1 Labs	4	5	6	7
Venetoclax 400 mg	Venetoclax 400 mg	Clinic Obinutuzumab IV Venetoclax 400 mg	Venetoclax 400 mg	Venetoclax 400 mg	Venetoclax 400 mg	Venetoclax 400 mg

Supplementary Table 1: Recommendations for TLS prophylaxis for CLL patients (per package insert).

Tumor Burden		Prophylaxis		Blood Chemistry Monitoring
		Hydration	Anti-uricemic	Setting and frequency of assessments
Low	All LN < 5 cm AND ALC < 25 x 10 ⁹ /L	Oral (1.5-2L)	Allopurinol	Outpatient: For first dose of 20 mg and 50 mg: Pre-dose, 6 to 8 hours, 24 hours For subsequent ramp-up doses: Pre-dose
Medium	Any LN 5 – 10 cm OR ALC ≥ 25 x 10 ⁹ /L	Oral (1.5-2L) and consider additional IV	Allopurinol	Outpatient: For first dose of 20 mg and 50 mg: Pre-dose, 6 to 8 hours, 24 hours For subsequent ramp-up doses: Pre-dose For first dose of 20 mg and 50 mg: Consider hospitalization for patients with CrCl < 80 ml/min; see below for monitoring in hospital

High	Any LN $\geq$ 10 cm OR ALC $\geq$ 25 x 10 ⁹ /L AND Any LN $\geq$ 5 cm	Oral (1.5-2L) AND IV (150-200 mL/h as tolerated)	Allopurinol and consider rasburicase if baseline uric acid is elevated	In hospital: For first dose of 20 mg and 50 mg: Pre-dose, 4, 8, 12, and 24 hours Outpatient: For subsequent ramp-up doses: Pre-dose, 6 to 8 hours, 24 hours
------	--	--	--	---

Supplementary Table 2: Scheduling Venetoclax and Obinutuzumab Ramp-Up in CLL.

Low/Medium Risk CLL Patients	High Risk CLL Patients
<u>Cycle 1 Day 1, 2, 8, 15:</u> · Labs (CMP, CBC, etc.) · Infusion (obinutuzumab)	<u>Cycle 1 Day 1, 2, 8, 15:</u> · Labs (CMP, CBC, etc.) · Infusion (obinutuzumab) –
<u>Ven Week 1 Day 1 (Cycle 1 Day 22)</u> · Labs 0800 · Clinic 0900 - o PharmD - o Provider · Infusion 1600	<u>Ven Week 1 Day 1 (Cycle 1 Day 22)</u> · Admission required
<u>Week 1 Day 2</u> · Labs 0800 · Infusion 0830	<u>Ven Week 1 Day 6 (day prior to admission)</u> · Labs · PharmD or Provider · Infusion (Cycle 2 obinutuzumab)
<u>Week 2 Day 1 (Cycle 2 Day 1)</u> · Labs 0800 · Clinic 0900 - o PharmD - o Provider · Infusion 1200 (obinutuzumab) - o 6 hour post ven labs	<u>Week 2 Day 1</u> · Admission required
<u>Week 2 Day 2</u> · Labs 0800 · Infusion 0830	<u>Week 3 – 5 Day 1</u> · Labs 0800 · Clinic 0900 - o PharmD - o Provider · Infusion 1600
<u>Week 3 – 5 Day 1</u> · Labs 0800 · Clinic 0900 - o PharmD - o Provider · Infusion 1000 – possible fluids	<u>Week 3 – 5 Day 2</u> · Labs 0800 · Infusion 0830
<u>Cycle 3-6 Day 1</u>	<u>Cycle 3-6 Day 1</u> · Labs · Provider · Infusion (obinutuzumab)

· Labs · Provider · Infusion (obinutuzumab)	
---	--